Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Graphite Bio stock

Learn how to easily invest in Graphite Bio stock.

Graphite Bio is a biotechnology business based in the US. Graphite Bio shares (GRPH) are listed on the NASDAQ and all prices are listed in US Dollars. Graphite Bio employs 114 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy Graphite Bio stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – GRPH. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award

eToro


  • Trade stocks and ETFs for $0 and no annual fee
  • Minimum deposit of $10 required
  • FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100

Promoted for easy user experience

Robinhood


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Graphite Bio stock price (NASDAQ: GRPH)

Use our graph to track the performance of GRPH stocks over time.

Graphite Bio shares at a glance

Information last updated 2023-01-25.
Latest market close$2.25
52-week range$1.59 - $11.30
50-day moving average $2.96
200-day moving average $3.19
Wall St. target price$6.86
PE ratio 0.3687
Dividend yield $0 (0%)
Earnings per share (TTM) $5.18

Buy Graphite Bio stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
eToro
Stocks, Options, ETFs, Cryptocurrency
$0
$10
FINDER EXCLUSIVE: Get $15
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
$0
$0
N/A
Winner of Finder’s Best Overall Stock Broker award.
loading

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Graphite Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Graphite Bio price performance over time

Historical closes compared with the close of $2.25 from 2023-02-01

1 week (2023-01-26) 16.58%
1 month (2022-12-30) -32.23%
3 months (2022-11-02) -35.71%
6 months (2022-08-02) -29.02%
1 year (2022-02-02) -75.57%
2 years (2021-01-29) N/A
3 years (2020-01-29) N/A
5 years (2018-01-29) N/A

Is Graphite Bio stock undervalued or overvalued?

Valuing Graphite Bio stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Graphite Bio's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Graphite Bio's P/E ratio

Graphite Bio's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Graphite Bio shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Graphite Bio's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

    Graphite Bio financials

    Gross profit TTM $0
    Return on assets TTM -16.28%
    Return on equity TTM -26.62%
    Profit margin 0%
    Book value $5.44
    Market capitalisation $111.1 million

    TTM: trailing 12 months

    Graphite Bio share dividends

    We're not expecting Graphite Bio to pay a dividend over the next 12 months.

    Graphite Bio overview

    Graphite Bio, Inc. , a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc. , and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc.

    Frequently asked questions

    What percentage of Graphite Bio is owned by insiders or institutions?
    Currently 9.521% of Graphite Bio shares are held by insiders and 92.624% by institutions.
    How many people work for Graphite Bio?
    Latest data suggests 114 work at Graphite Bio.
    When does the fiscal year end for Graphite Bio?
    Graphite Bio's fiscal year ends in December.
    Where is Graphite Bio based?
    Graphite Bio's address is: 201 Haskins Way, South San Francisco, CA, United States, 94080
    What is Graphite Bio's ISIN number?
    Graphite Bio's international securities identification number is: US38870X1046

    More guides on Finder

    Ask an Expert

    Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

    By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

    Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
    Go to site